Target intelligence / Profile preview

Clostridium perfringens toxin

Molecular classification
Bacterial toxin, Enzyme (for alpha toxin, as phospholipase C), Pore-forming toxin (e.g., beta, epsilon, enterotoxin), Cytotoxin, Other
01

Overview

Clostridium perfringens toxins are a family of toxic proteins secreted by the bacterium Clostridium perfringens, a Gram-positive anaerobic bacillus responsible for a range of serious diseases in humans and animals. The organism is classified into toxinotypes (A-G) based on its combination of major toxin production, the most significant being alpha (CPA), beta (CPB), epsilon (ETX), iota (ITX), and enterotoxin (CPE), each with distinct pathogenic mechanisms[1][2][4][5]. These toxins act through destroying cell membranes—by phospholipase activity (alpha toxin/CPA), forming pores (beta, epsilon, enterotoxin), or damaging the cytoskeleton (iota toxin), among others. The toxins are key virulence factors, driving diseases such as gas gangrene, necrotizing enteritis, and enterotoxemia, and are highly potent; for example, epsilon toxin is one of the most toxic proteins known. Therapeutic targeting focuses on neutralization or inhibition of toxin activity, with some vaccines developed for veterinary use and antibody-based therapies under research. The term "Clostridium perfringens toxin" is not a single entity but refers to a spectrum of toxins; thus, use of this term may be imprecise unless referring to a specific toxin type[1][2][4]. Caveat: - "Clostridium perfringens toxin" is not a single molecule but refers to a group of toxins. For precise scientific work or therapeutic targeting, the specific toxin should be identified—e.g., "Clostridium perfringens alpha toxin," "Clostridium perfringens beta toxin," etc. The entry is thus considered "is_incorrect: true" in terms of specificity, though there are bona fide protein toxins produced by this bacterium[1][2][4].

Other names
Alpha toxinBeta toxinEpsilon toxinIota toxinPerfringolysin OEnterotoxinCPBCPAETXITXCPENetBTpeL
02

Mechanism of action

Inhibition of toxin binding to host receptors (e.g., anti-toxin antibodies); Inhibition of toxin enzymatic activity (e.g., phospholipase inhibitors for alpha toxin); Blocking pore formation (e.g., synthetic blockers, antibodies); Immunization/vaccination to generate protective immunity

03

Biological functions

Cell membrane disruptionPore formation in cell membranesCell necrosisCell lysisApoptosis inductionImmune response modulationOther
04

Disease associations

InfectionGas gangrene (clostridial myonecrosis)Necrotizing enteritisEnterotoxemiaFood poisoningHemorrhagic and necrotic disease (especially of intestine)Other
05

Safety considerations

Severe cytotoxicity and tissue damageRisk of shock, sepsis, multi-organ failureHigh potency; extremely low lethal doses for some toxins (e.g., epsilon)Difficulties in neutralizing toxin after onset of symptomsResistance to therapy if not administered early
06

Interacting drugs

Antitoxins (antibody-based therapeutics)

4 more in the full profile.

07

Biomarkers

Presence of specific toxin genes (e.g., cpa for alpha toxin, cpb for beta, cpe for enterotoxin, etx for epsilon, etc.)Detection of toxin proteins in blood or tissuesDetection of *Clostridium perfringens* in clinical specimens

Beyond the preview

Go deeper on Clostridium perfringens toxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clostridium perfringens toxin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call